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Corticotropin Releasing Factor Receptor 1±Deficient
Mice Display Decreased Anxiety, Impaired Stress
Response, and Aberrant Neuroendocrine Development
1996; Vale et al., 1997). CRFR1 and CRFR2 share ap-
proximately 71% amino acid sequence similarity (Grigo-
riadis et al., 1996; Vale et al., 1997) and are both phar-
macologically distinct and unique in their expression
patterns within the brain and peripheral tissues. In the
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Perrin et al., 1995). Each receptor subtype can bind both
CRF and urocortin (UCN), the newly described CRF-
related ligand (Vaughan et al., 1995). UCN may be theSummary
putative endogenous ligand for CRFR2, since CRFR2
binds UCN with an approximately 40-fold higher affinityCorticotropin releasing factor (CRF) is a major integra-
than it binds CRF (Vaughan et al., 1995). However, thetor of adaptive responses to stress. Two biochemically
specific CRF receptor molecules that trigger each of theand pharmacologically distinct CRFreceptor subtypes
adaptive responses are unclear.(CRFR1 and CRFR2) have been described. We have
The developmental roles of the various componentsgenerated mice null for the CRFR1 gene to elucidate
of the CRF system have not been elucidated. The ex-the specific developmental and physiological roles of
pression of CRF and its receptors is temporally andCRF receptor mediated pathways. Behavioral analy-
spatially regulated during embryonic and neonatal de-ses revealed that mice lacking CRFR1 displayed mark-
velopment (Muglia et al., 1995; Avishai-Eliner et al.,edly reduced anxiety. Mutant mice also failed to exhibit
1996). Mice null for the CRF gene display endocrine andthe characteristic hormonal response to stress due
developmental abnormalities (Muglia et al., 1995). Theto a disruption of the hypothalamic-pituitary-adrenal
presence of multiple CRF receptor species and addi-(HPA) axis. Homozygous mutant mice derived from
tional CRF-related ligands necessitates a systematiccrossing heterozygotes displayed low plasma cortico-
evaluation of the biological responses mediated by eachsterone concentrations resulting from a marked agen-
receptor subtype.esis of the zonafasciculata region of the adrenal gland.
To dissect the specific developmental and biologicalThe offspring from homozygote crosses died within
roles of CRF receptor±mediated pathways, we have48 hr after birth due to a pronounced lung dysplasia.
generated mice deficient in CRFR1 via homologous re-The adrenal agenesis in mutant animals was attributed
combination in embryonic stem (ES) cells. CRFR1 wasto insufficient adrenocorticotropic hormone (ACTH)
found to be absolutely required for adrenal gland devel-production during the neonatal period and was res-
opment and a normal endocrine response to stress. Incued by ACTH replacement. These results suggest
addition, the CRFR1 mutants showed a markedly de-that CRFR1 plays an important role both in the devel-
creased anxiety response. The CRFR1-deficient miceopment of a functional HPA axis and in mediating be-
provide a useful model system for characterization ofhavioral changes associated with anxiety.
the CRF receptor subtypes involved in various adaptive
responses.Introduction
In mammals, corticotropin releasing factor (CRF) is a Results
major integrator of the endocrine, neuroendocrine, auto-
nomic, and behavioral responses to stress (Vale et al., Generation of CRFR1-Deficient Mice
1981; Owens and Nemeroff, 1991). The biological ac- To generate CRFR1-deficient mice, a targeting vector
tions of CRF family members are mediated via binding was constructed in which the portion of the CRFR1 gene
to specific, high-affinity, G protein±coupled membrane encoding the last 12 amino acids of the first extracellular
receptors. Two distinct CRF receptor subtypes, CRFR1 domain through the fourth transmembrane domain was
and CRFR2, have been characterized (Grigoriadis et al., replaced with a neomycin resistance gene cassette (Fig-
ure 1A). Translation of the resulting disrupted CRFR1
mRNA would presumably result in a nonfunctional re-§Both authors contributed equally to this work.
ceptor protein. Six of 500 neomycin-resistant colonies‖ Present address: Department of Animal Science, Michigan State
screened were positive as assessed by Southern analy-University, East Lansing, Michigan 48824-1225.
¶ To whom correspondence should be addressed. sis with an external probe (Figure 1B). Cells from two
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Table 1. Concentrations of Plasma Corticosterone in the
Circulation of CRFR1 Mutant and Control Mice at 6 am and 4 pm
Plasma corticosterone (ng/ml)
Genotype and sex am pm
Male CRFR1 mutant mice 4.13 6 1.29 2.40 6 0.37
Male control mice 11.52 6 4.45 64.22 6 10.67a
Female CRFR1 mutant mice 8.02 6 2.76 8.37 6 3.99
Female control mice 20.06 6 5.52 74.47 6 21.26a
a P , 0.001, am versus pm.
was not observed in female mutant mice or in control
mice. To determine whether the targeted deletion re-
sulted in a null mutation, cultured pituitary cells from
control and mutant mice were treated for 1 hr with 0±10
nM CRF, and the levels of adrenocorticotropic hormone
(ACTH) in culture medium were measured. CRF treat-
ment of control pituitary cells resulted in a dose-depen-
dent increase in ACTH secretion (Figure 1C). In contrast,
treatment of CRFR1-deficient pituitary cells with 0±10
nM CRF did not increase ACTH secretion (Figure 1C).
Accumulation of cAMP by mutant pituitary cells also was
blunted following CRF treatment (Figure 1C). Reverse
transcription-polymerase chain reaction analysis of
mRNA collected from the cerebellum of homozygous
mutant animals also confirmed the presence of the dele-
tion within the CRFR1 gene (data not shown). Thus,
we conclude that the targeted mutation resulted in a
disrupted CRFR1 gene and loss of receptor function.
Mice Lacking CRFR1 Display a Pronounced
Adrenal Deficiency
CRF is known to play a key role in the regulation of the
hypothalamic-pituitary-adrenal (HPA) axis and in many
central responses to stress (Owens and Nemeroff, 1991).
As an initial assessment of function of the HPA axis in
mutant animals, plasma samples were collected fromFigure 1. Generation of the CRFR1-Deficient Mice
male and female control and mutant mice at 6:00 am(A) (Upper) Genomic organization of the CRFR1 gene showing exons
and 4:00 pm. CRFR1 mutants (males and females) had4±13. (Middle) Targeting construct utilized for homologous recombi-
very low plasma corticosterone concentrations as com-nation. The HindIII-XbaI fragment (exons 5±8) encoding the last 12
amino acids of thefirst extracellular domain through thefourth trans- pared with control mice. In particular, the characteristic
membrane domain was deleted and replaced with a PGK-neo cas- diurnal rise in circulating corticosterone that occurs in
sette. (Bottom) The resulting mutated locus following homologous the afternoon was absent in the mutant mice (Table 1).
recombination.
Histological analysis revealed a marked decrease in the(B) The disrupted CRFR1 allele was identified by Southern analysis
size of the zona fasciculata (corticosterone producing)with a BamHI-HindIII external probe which detected a 8.0 kb control
region of the adrenal glands collected from CRFR1-defi-band and a 6.3 kb mutated band, respectively; J1 (parental ES cell
line), CRFR1 1/2 (ES cell clone heterozygous for the mutation). cient mice (Figure 2A). Other regions of the adrenal
(C) CRF-stimulated ACTH secretion and cAMP accumulation by glands of mutant mice (zona glomerulosa, zona reticu-
monolayer cultures of whole pituitaries collected from control and laris, and medulla) appeared normal. In addition, plasma
CRFR1 mutant mice (CRFR1 2/2).
concentrations of aldosterone, produced by the zona
glomerulosa region of the adrenal gland, were similar
between mutant and control mice (data not shown).
Therefore, the adrenal deficiency in the CRFR1-deficient
targeted ES cell lines were injected into C57 BL/6 blasto- mice appears specific to the corticosterone-producing
cysts to generate chimeric founder mice, and germ-line region of the adrenal gland.
transmission of the disrupted allele was obtained. In
general, homozygous mutant mice born from mating
of heterozygotes developed normally and were fertile. CRFR1 Mutant Mice Display an Impaired
Neuroendocrine Response to StressHowever, a 15% mortality rate was observed in the male
CRFR1 mutant mice. The death loss occurred primarily Activation of the HPA axis and the accompanying hor-
monal response to stress is triggered by increased CRFwhen animals were between 3 and 12 weeks of age and
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Figure 2. Histological and Immunohisto-
chemical Evaluation of the Pituitary±Adrenal
Axis in the CRFR1 Mutant Mice
(A) Pronounced atrophy of adrenal glands of
CRFR1 mutant mice. Adrenal glands of fe-
male control and CRFR1 2/2 mice were sec-
tioned and stained with hematoxylin and eo-
sin. Note the overall size of adrenal gland was
decreased in mutant mice (low magnification,
upper panels). At higher magnification (lower
panels), the marked hypoplasia of the zona
fasciculata (ZF) region was observed. The
zona glomerulosa (ZG), zona reticularis (ZR),
and medullary (M) regions were relatively un-
affected.
(B) Corticotrope development in CRFR1 mu-
tant mice. Pituitary glands from both control
and CRFR1 mutant mice were sectioned, and
corticotropes were localized with anti-ACTH
antibodies. No gloss anatomical differences
were observed in all three lobes of the pitu-
itary glands. No difference in the number of
corticotropes was observed. A, I, and P: ante-
rior, intermediate, and posterior pituitary
lobe, respectively.
secretion into the hypothalamic-pituitary-portal system increase circulating ACTH in the CRFR1-deficient mice
and the amplitude of their corticosterone response wasby neurons in the paraventricular region of the hypothal-
greatly blunted compared to control mice (Tables 2 andamus (Owens and Nemeroff, 1991). This elevation of CRF
3, respectively). These results indicate that the endo-in the portal blood leads to increased ACTH secretion by
crine response to stress is severely compromised in thethe pituitary gland and the accompanying increase in
corticosteroid secretion by the adrenal gland (Owens
and Nemeroff, 1991). To determine whether function of
Table 2. Effect of Restraint Stress on Plasma ACTHthe pituitary and adrenal gland in response to stress was
Concentrations in CRFR1 Mutant and Control Miceimpaired in CRFR1-deficient animals, male and female
control and mutant mice were subjected to a brief physi- Plasma ACTH (pg/ml)
cal-restraint stress. Plasma concentrations of cortico-
Genotype and sex Pre-stress Post-stress
sterone and ACTH were measured in samples collected
Male CRFR1 mutant mice 72.07 6 17.90 130.73 6 14.54prior to and immediately after a 10-min restraint period.
Male control mice 70.60 6 13.35 791.98 6 103.87a
Control animals, males and females, responded with a Female CRFR1 mutant mice 66.60 6 13.67 106.83 6 10.55
significant increase in ACTH and corticosterone secre- Female control mice 46.50 6 6.41 446.25 6 69.97a
tion following restraint stress (Tables 2 and 3, respec-
a P , 0.001, pre-stress versus post-stress.
tively). In contrast, restraint stress did not significantly
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Table 3. Effect of Restraint Stress on Plasma Corticosterone
Concentrations in CRFR1 Mutant and Control Mice
Plasma corticosterone (ng/ml)
Genotype and sex Pre-stress Post-stress
Male CRFR1 mutant mice 2.80 6 0.95 18.90 6 5.05
Male control mice 17.53 6 7.08 129.86 6 8.88a
Female CRFR1 mutant mice 2.59 6 0.55 33.52 6 8.81b
Female control mice 22.69 6 7.35 175.53 6 8.66a
a P , 0.001, b P , 0.05, pre-stress versus post-stress.
CRFR1 mutant mice. However, female mutant mice were
still able to elicit a rudimentary corticosterone response
to stress even in the absence of CRFR1 (Table 3). A
significant corticosterone response to stress was also
reported for the female mice lacking CRF (Muglia et al.,
1995).
Mice Lacking CRFR1 Display Normal Basal ACTH
Secretion and Corticotrope Development
CRFR1 is the predominant CRF receptor subtype ex-
pressed in the pituitary gland (Grigoriadis et al., 1996).
It can stimulate proliferation of pituitary corticotropes
(ACTH producing cells) in vivo (Gertz et al., 1987) and
hence has been postulated to play a role in their devel-
opment. Histological and immunocytochemical analy-
ses of pituitary glands from mutant mice revealed no
gross anatomical defects and a normal complement of
corticotropes (Figure 2B). A critical requirement of CRF/
Figure 3. Increased Expression of CRF but Not Arginine Vasopres-CRFR1 for normal corticotrope development, therefore,
sin within the Hypothalamus of CRFR1±Deficient Miceseems unlikely. In addition, basal ACTH concentrations
Immunohistochemical localization of CRF (A) andarginine vasopres-in the circulation of mature mutant mice prior to restraint
sin (B) in the paraventricular nuclei of the hypothalamus (PVN) of
stress were similar to those of control mice (Table 2). control and CRFR1 mutant mice revealed increased CRF expression
Therefore, secretion of ACTH in mature animals under in the mutant animals.
basal conditions occurs normally in the absence of
CRFR1.
to produce CRF, such as the amygdala, CRF expression
in mutant mice was not different from controls (data notIncreased Expression of CRF in the Paraventricular
Nuclei of the Hypothalamus shown). Therefore, CRFR1 deficiency leads to increased
CRF expressionspecificallywithin thePVN ofmutant mice.Loss of CRFR1-dependent pathways in mutant animals
may potentially be compensated by changes in the lo-
calization and/or level of expression of other compo- Neonatal Mortality of the Progeny of Homozygous
CRFR1 Mutant Mice and In Utero Rescuenents of theCRF system. Therefore, immunohistochemi-
cal and in situ hybridization analyses were conducted with Corticosterone
Heterozygous CRFR1 mutant females were fertile andto characterize changes in the expression of other key
components of the CRF system within the brains and exhibited no obvious reproductive abnormalities. As
mentioned previously, the progeny born to heterozy-pituitaries of CRFR1-deficient mice. No changes in spa-
tial distribution or levels of CRFR2 expression were ob- gous CRFR1 mutant mice were viable at birth and dis-
played a normal neonatal survival rate. To characterizeserved in the brains or the pituitary glands of mutant
mice (data not shown). Immunohistochemical analyses further the reproductive and developmental capacity of
the CRFR1-deficient mice, male and female homozy-revealed that expression of CRF within the paraventricu-
lar nuclei of the hypothalamus (PVN) of CRFR1-deficient gous mutant mice were intercrossed. While no markedly
obvious differences in fertility were noted, virtually allmice was markedly increased compared to that of wild-
type mice (Figure 3A). Increased CRF mRNA expression of the progeny born to the homozygous CRFR1 mutant
females died within 48 hr after birth. Given the observedwas also detected within the PVN of mutant mice (data
not shown). Arginine vasopressin, originating in part adrenal defect in mutant females and the established
requirement of corticosteroids for neonatal lung matura-from the same neurons in the PVN that synthesize CRF,
is also a key regulator of corticotrope function. In con- tion (Ballard, 1989), we suspected that these animals
died from neonatal respiratory distress. Histologicaltrast to CRF, no detectable alteration in arginine vaso-
pressin expression was observed within the PVN of mu- analysis of lungs collected on postnatal day 1 revealed
a marked lung dysplasia in offspring born to femaletant mice (Figure 3B). In other regions of the brain known
Physiological Effect of CRF Receptor 1 Mutation
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Figure 4. The Progeny of Homozygous CRFR1
Mutant Females Display a Marked Lung Dys-
plasia That Can Be Rescued by In Utero Treat-
ment with Corticosterone
Lungs from neonates at postnatal day 1 were
fixed, sectioned, and stained with hematoxy-
lin and eosin.
(A) Control lungs show thin alveolar septae
and normal air space expansion.
(B) Mutant lungs display alveolar collapse (*)
and reactive emphysema with intra-alveolar
hemorrhage and hemosiderotic deposition.
Hyaline membranes are not evident.
(C) Lungs from mutant neonates treated in
utero with corticosterone in maternaldrinking
water.
homozygous mutant mice in comparison with control CRFR1 mutant mice was due to insufficient trophic hor-
mone (ACTH) support during neonatal adrenal develop-mice (Figure 4). Mutant lungs displayed alveolar collapse
and reactive emphysema with intra-alveolar hemor- ment. To test this possibility, an ACTH treatment regime
was initiated. Mice were injected twice daily with ACTHrhage and hemosiderotic deposition (Figure 4B). We
then investigated whether corticosterone treatment from postnatal days 10±21. As a result, the overall adre-
nal size and the width of the zona fasciculata regioncould prevent the neonatal lung dysplasia and accom-
panying accentuated mortality of progeny born to homo- were significantly increased in comparison with diluent
injected mutant mice (Figure 5B). Hence, the adrenalzygous mutant mice. Results of these experiments indi-
cated that in utero treatment of homozygous mutant defect likely results from reduced circulating ACTH
concentrations in the mutant mice during the neonatalfemales with corticosterone in the drinking water from
embryonic day 12 through postnatal day 14 resulted in period of adrenal maturation. These results suggest that
functional connections between the hypothalamus andnormal lung maturation in their progeny. Histological
analysis of lungs collected on postnatal day 1 following the pituitary gland are absolutely critical for normal post-
natal development and maturation of the adrenal cortex.in utero corticosterone treatment revealed a normal ar-
chitecture, with thin alveolar septae and normal air
space expansion (Figure 4C). In utero corticosterone
treatment also resulted in a normal postnatal survival CRFR1 Mutant Mice Display Markedly
Reduced Anxietyrate of progeny born to homozygous mutant females
(data not shown). Therefore, we conclude that the inade- Following exposure to stress, animals display distinct
behavioral changes suggestive of an anxiety response.quate lung maturation and reduced postnatal survival
of progeny born to homozygous CRFR1 mutant mice is A large number of pharmacological studies indicate that
a result of insufficient maternal corticosterone pro- CRF mediates many of the behavioral responses to
duction. stress (Koob et al., 1994). Therefore, we evaluated
whether mice lacking CRFR1 displayed a normal anxiety
response by testing male control and mutant mice inHormonal Rescue of the Adrenal Defect
two well-defined behavioral paradigms.in CRFR1-Deficient Mice
The behavioral responses of CRFR1-deficient mice inFurther characterization of the CRFR1 mutant mice was
an anxiogenic-like environment were examined using aconducted to delineate the basis for the marked adrenal
dark±light emergence task and compared with controlatrophy in homozygous animals and to determine
mice. The mutant mice had a tendency to exit the smallwhether the adrenal defect was first manifest during
chamber into the open field (aversive environment) withprenatal versus postnatal life. Adrenal glands from con-
a shorter latency compared with the control mice (datatrol mice and from mutant mice were collected on post-
not shown) and spent a longer time in the open fieldnatal day 3 and assessed histologically. No obvious
(P , 0.05; Figure 6A). The mean time spent in the opendifferences in morphology of mutant adrenal glands
field per exit was also greater for the mutant mice thanwere detected (Figure 5A). Therefore, the onset of the
the control mice (mutant, 19.9 6 7.53 s versus control,adrenal defect in CRFR1 mutant mice likely occurs later
3.8 6 3.2 s; P , 0.05). To determine whether the reducedduring neonatal life.
sensitivity of CRFR1 mutant mice to anxiogenic-likeIn hypophysectomized adult animals, ACTH replace-
stimuli was due to a difference in reactivity to novelty,ment is required for the maintenance of the zona fascicu-
locomotor activity was measured in a novel environ-lata region (Idelman 1970; Wyllie et al., 1973). Assay
ment, under the same light conditions as for the dark±of plasma ACTH concentrations on postnatal day 10
light emergence task. As illustrated in Figure 6B, therevealed that the mutant mice have significantly lower
total zone entries for the first 5 min, corresponding tolevels than control mice (Figure 5C; P , 0.02). These
results raise the possibility that the adrenal atrophy in the duration of the dark±light emergence protocol, were
Neuron
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Figure 6. Behavior of the CRFR1 Mutant Mice in the Dark±Light
Emergence Task and Elevated Plus-Maze Was Determined and
Compared with Control Mice
For the dark±light emergence task, mice were placed into the small
chamber at the start of the 5-min session.
(A) Total time (s) mice spent out of the chamber (control n 5 6,
mutant n 5 6; mean 6 SEM; *P , 0.05).
(B) Acute locomotor activity of control and mutant mice in a novel
environment was also determined. Total zone entries (mean 6 SEM)
of control and mutant mice over a 5-min period during the light
cycle were not different (P . 0.05).
(C) Behavior of the mutant mice in the elevated plus maze. Percent-
age of time spent in the open arms (P , 0.0002) and the number
of visits to the open arms (P , 0.05) were greater in the mutant than
the control mice (control n 5 8, mutant n 5 8; mean 6 SEM).
(D) Similar behavioral responses were observed in mutant and con-
trol mice (control n 5 9, mutant n 5 8) subjected to corticosterone
replacement, suggesting that the reduced anxiety response is not
due to decreased levels of corticosterone in the mutant mice. The
corticosterone replacement study was conducted with two groupsFigure 5. Hormonal Rescue of the Adrenal Defect in CRFR1-Defi-
that received corticosterone in the drinking water (D) and two groupscient Mice
receiving vehicle, e.g., water (C).
(A) Hematoxylin and eosin stained sections of adrenals collected
from control and CRFR1-deficient mice on postnatal day 3 demon-
strating no difference in adrenal morphology during the early postna- and mutant (n 5 8) mice were treated with or without
tal period. 10 mg/ml corticosterone in the drinking water for 13days
(B) Adrenal glands collected from control mice and from CRFR1 prior to evaluation in the elevated plus maze test. The
mutant mice treated twice daily from postnatal days 10±21 with
levels of corticosterone in steroid-treated mutant maleACTH or diluent alone. Note the increased size and thickness of the
mice were increased to similar levels as in the controlzona fasciculata region of the adrenal gland from CRFR1 mutant
mice treated with ACTH. mice (steroid-treated control, 15.9 6 5.9; steroid-treated
(C) Plasma ACTH concentrations on day 10 of postnatal life in sam- mutant, 13.8 6 3.0; also compared with the values for
ples collected from CRFR1 mutant or control mice (mean 6 SEM; male mice in Table 1). A significant genotype (or strain)
**P , 0.02). effect was found for both percent open arm entries (P ,
0.0002) and percent time in open arms (P , 0.05). Thus,
the CRFR1-deficient mice visited and spent more timenot different between the two groups. Therefore, differ-
ences in reactivity to novelty cannot explain the in- in the open arms of the apparatus than control mice,
indicative of a reduced anxiety response. Neither a sig-creased tendency of mutant mice toexit thesmall cham-
ber in the dark±light emergence task. nificant drug treatment effect nor a significant strain 3
drug treatment interaction was obtained for both per-Anxiety levels displayed by mutant and control mice
were also compared using another animal model, cent open-arm entries and percent time in the open
arms. Therefore, corticosterone administration did notnamely, the evaluated plus maze test. Because plasma
levels of corticosterone in mutant mice are significantly affect the behavioral performance of either control or
CRFR1-deficient mice in the elevated plus maze modellower than in control mice, the altered anxiety response
in mutant mice may be due to low levels of corticoste- for anxiety. A two-way analysis of variance (ANOVA)
performed on closed-arm entries, a validated measurerone. To exclude this possibility, both control (n 5 9)
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of activity in this test, did not reveal a significant strain as the amygdala. The increased expression of CRFR1
in the PVN may be due to the reduced negative feedbackor drug treatment effect, nor did it reveal a significant
strain by drug treatment interaction. These results indi- effects of corticosteroids. In rats, both CRF and arginine
vasopressin expression in the PVN are inhibited by corti-cate that the behavior of the mutant mice in the plus
maze was not due to a general increase in activity of costeroids (Sawchenko, 1987) and elevated by adrena-
lectomy (Sawchenko et al., 1984). However, expressionthe mutant mice. We conclude that the mutant mice
showed an increased approach to environments gener- of arginine vasopressin (another key regulator of ACTH
secretion) in the PVN of CRFR1-deficient mice was simi-ally considered as aversive in rodents (Denenbergh,
1967; Archer, 1973; Crawley and Goodwin, 1980; Misslin lar to that of control animals. Regardless, the normal
circulating ACTH levels of mature mutant mice cannotet al., 1989) and were less sensitive to the anxiogenic-
like stimuli. Taken together, these results demonstrate be accounted for by increased arginine vasopressin
stimulation of corticotrope function.that CRFR1 is required for a normal anxiety response.
CRFR1 mutant females were fertile and exhibited no
obvious reproductive abnormalities. The progeny bornDiscussion
to heterozygous mutant females displayed normal neo-
natal survivability, while the progeny born to homozy-In this study, we have generated mice with a targeted
disruption in the CRFR1 locus by gene targeting in ES gous mutant females died within 48 hr after birth due to
lung dysplasia. A similar etiology and neonatal mortalitycells. Cultured pituitary cells collected from mutant ani-
mals failed to display an increase in cAMP accumulation was reported for both the CRF-deficient mice (Muglia
et al., 1995) and for mice with a targeted disruption inand ACTH secretion upon CRF treatment, verifying that
the mutation caused a loss of receptor function. Disrup- the glucocorticoid receptor gene (Cole et al., 1995). In
the progeny of homozygous CRFR1 mutant females, thetion of the CRFR1 gene resulted in distinct develop-
mental defects in the mutant animals. More specifically, neonatal mortality was a result of maternal corticoste-
rone deficiency, leading to inadequate fetal/neonataltheCRFR1-deficient mice exhibited a pronounced agen-
esis of the zona fasciculata region of the adrenal gland. lung maturation. In the present study, we were able to
restore the survival of the offspring by corticosteroneMarkedly reduced circulating corticosterone concentra-
tions accompanied theadrenal defect inmature animals, supplementation beginning in utero. A similar paradigm
was used to rescue progeny born to homozygous CRFverifying both a structural and a functional abnormality
in the CRFR1 mutants. Mice with a targeted disruption mutant mice (Muglia et al., 1995). Corticosteroid treat-
ment is commonly used to treat respiratory distress syn-in the CRF gene also exhibit a similar adrenal defect
(Muglia et al., 1995). drome in prematurely born infants (Ballard, 1989).
To investigate the behavioral consequences of CRFR1The ability of ACTH replacement during early postna-
tal life to restore adrenal gland development suggests deficiency, the responses of mutant and control mice
were evaluated in two experimental models of anxiety.that there is a critical window of time during neonatal
development when CRFR1-dependent ACTH secretion In both paradigms, the CRFR1 mutant mice consistently
showed a reduced anxiety-like response. There was nois absolutely required for full adrenal maturation. Onset
of the adrenal defect during prenatal development of effect of genotype on locomotor activity or on closed
arm activity in the elevated plus maze. Closed arm activityCRFR1-deficient mice seems unlikely. Consistent with
our results, initial differentiation of the adrenal cortex is a validated measure of activity, but not of anxiogenic-
like effects, in this test. The behavioral response of theoccurs during prenatal life (Daikoku et al., 1976). Further-
more, histological analysis of adrenal glands collected mutant mice was not affected by corticosterone replace-
ment, demonstrating that the reduced anxiogenic-likeon postnatal day 3 revealed no detectable differences
between the CRFR1 mutant and control mice. These behavior is not due to low circulating corticosterone
concentrations. Consistent with our results, prior stud-results suggest that a functional hypothalamic±pituitary
axis in neonatal animals is required for normal develop- ies have demonstrated that the anxiogenic-like effects
of CRF in rats also are independent of activation of thement of the adrenal gland.
In the present study, circulating ACTH levels in mature pituitary-adrenal axis (Britton et al., 1986).
Previous data in rats injected centrally with CRF an-mutant animals were similar to those in control mice.
The fact that mutant animals are not subjected to the tagonists and antisense oligonucleotides suggest that
the behavioral and physiological responses to stresspotent inhibitory effects of corticosterone on ACTH syn-
thesis and secretion (Keller Wood and Dallman, 1984) may depend on CRF actions in the brain (Takahashi et
al., 1989; Swiergiel et al., 1993; Koob et al., 1994; Skutellamay account for their apparently normal ACTH levels.
Nevertheless, the normal circulating ACTH concentra- et al., 1994; Martinez et al., 1997). Chronic central admin-
istration of antisense CRFR1 oligonucleotides reducestions in mature mutant animals are not sufficient to re-
store maturation and normal function of the adrenal the anxiety response of rats when tested in a defensive
withdrawal paradigm (Heinrichs et al., 1997). In addition,gland. Therefore, the adrenal defect appears to result
from a lack of CRFR1-mediated ACTH secretion during treatment of rats with the nonpeptide CRF receptor an-
tagonist CP-154,526, with a high selectivity for CRFR1,neonatal life.
A compensatory increase in expression of the pre- blocks the anxiogenic-like effects of centrally adminis-
tered CRF (Schulz et al., 1996). Consistent with the cur-dominant ligand for CRFR1 (CRF) was detected within
the PVN of CRFR1-deficient mice. The increase in CRF rent literature, our results demonstrate that CRFR1 plays
a role in CRF-mediated behavioral responses.mRNA and protein was limited to the PVN and not de-
tected in other CRF producing regions of the brain such While two specific CRF receptor subtypes have been
Neuron
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Primary cultures of mouse whole pituitary cells were used to verifydescribed to date, the precise role of each receptor in
that the deletion in the CRFR1 gene resulted in a null mutation.mediating the biological responses to CRF and its re-
Briefly, whole pituitaries were collected from 8- to 10-week-old fe-lated ligands underundisturbed and stressful conditions
male mutant and control mice (approximately ten mice per group)
have not been completely elucidated. CRFR1 expres- and dispersed as described previously (Vale et al., 1983). The cells
sion within the brain and pituitary gland is regulated by were then washed in complete medium (bPJ) supplemented with
2% fetal bovine serum and established as monolayers (1.2 3 105stress (Rivest et al., 1995; Rabadan-Diehl et al., 1996)
cells/well/0.5 ml) in 48-well Costar (Cambridge, MA) plates pre-and by CRF and other modulators (Mansi et al., 1996;
coated with poly-d-lysine (20 mg/ml). After 3 days of recovery, thePozzoli et al., 1996), while expression of CRFR2 isconsti-
cells were equilibrated for 2 hr in bPJ medium containing 0.1%tutive under similar conditions (Rivest et al., 1995). These
bovine serum albumin and treated for 1 hr with 0±10 nM CRF in
results raise the possibility that CRFR1 is the major brain fresh medium. The medium was collected, and ACTH secretion
receptor mediating stress-related response to CRF. In (Diagnostic Products Corp., Los Angeles, CA) and cAMP (Biochemi-
cal Technologies, Inc., Cambridge, MA) were measured using radio-the present experiments, we clearly demonstrated that
immunoassay kits.the classical endocrine and behavioral responses to
stress require CRFR1. However, the stress-induced re-
Histological and Immunohistochemical Analysesduction of serum testosterone concentrations was not
For histological analyses, mutant and wild-type mice (n 5 3 per
diminished in male CRFR1 mutant mice (Smith et al., group; approximately 8±10 weeks of age unless specified otherwise)
unpublished data), indicating that the adaptive re- were perfused with 4% paraformaldehyde. After perfusion, tissues
sponses of an animal are not mediated solely through were dissected (lungs, adrenal glands, etc.) and postfixed for 24 hr
at 48C. Tissues were subsequently embedded in paraffin, sectionedCRFR1. Additional studies will be necessary to deter-
at 7 mm thickness, and stained with hematoxylin and eosin. Formine precisely which of the other responses to stress
immunohistochemical localization of CRF and arginine vasopressinare mediated by CRFR1. Chronic hyperactivation of the
(AVP) within the brain and of ACTH within thepituitary gland, animals
CRF system has been implicated in several affective were perfused with 4% paraformaldehyde and tissues were sec-
disorders, including anxiety, anorexia nervosa, and mel- tioned at 30 mm thickness. Immunohistochemical localization of
ancholic depression (Chrousos and Gold, 1992; Orth, CRF and AVP (Chan et al., 1993) and ACTH (Potter et al., 1994) was
conducted as described previously (n 5 3).1992). Additional clarification of the precise role of each
CRF receptor subtype may lead to the further develop-
Blood Collection and Hormone Analysesment and application of specific CRF receptor antago-
For all hormone analyses, animals (approximately 8±10 weeks of
nists for treatment and/or diagnosis of various neuro- age unless specified otherwise) were housed individually overnight
psychiatric disorders. prior to collection of plasma samples. Samples were collected by
In summary, targeted disruption of the CRFR1 gene retroorbital eye bleeding within 45 s of initial disturbance of the
cage. For determination of basal corticosterone concentrations,demonstrated a specific developmental role for CRFR1
blood samples were collected at 6:00 am from male and femalein allowing sufficient ACTH secretion for postnatal matu-
mutant and control mice (n 5 14 each) and also at 4:00 pm fromration and function of the corticosteroid-producing re-
male and female mutant and control mice (n 5 6, 6, 5, and 6, respec-gion of the adrenal gland. Mutation of the CRFR1 gene
tively). For evaluation of the endocrine response to stress, blood
also firmly established the requirement of this receptor samples were collected at 8:00 am from male and female CRFR1
for endocrine and behavioral responses to stress. Delin- mutant and control mice (n 5 6 per group). Animals were then
immediately subjected to a brief physical restraint stress (10-mineation of the precise contribution of other members of
restraint in a 50-ml conical tube with the bottom removed). A secondthe CRF system, both in development and in mainte-
blood sample was then collected and animals were immediatelynance of homeostasis, will require generation of animals
euthanized. For determination of circulating ACTH concentrationswith mutations in other componentsof the CRF signaling
during the early postnatal period, plasma samples were collected
pathways. from CRFR1-deficient (n 5 5) and control mice (n 5 7) on postnatal
day 10. Circulating corticosterone concentrations were also deter-
mined in mutant (n 5 9) and control (n 5 8) mice treated with orExperimental Procedures
without corticosterone (mutant n 5 8, control n 5 8). Two hours
after completion of the plus-maze test, mice were sacrificed byTargeting Vector Construction, ES Cell Culture,
decapitation. Trunk blood was collected and plasma extracted forand Verification of Null Mutation
subsequent corticosterone assay. Plasma concentrations of ACTHCloned genomic DNA corresponding to the CRFR1 locus was iso-
were determined as described above. Differences in circulating hor-lated from a mouse strain 129 genomic DNA library. A targeting
mone concentrations were determined by ANOVA.construct was generated whereby exons 5±8 of the CRFR1 gene
encoding the last 12 amino acids of the first extracellular domain
In Utero Corticosteroid Rescue of Lung Dysplasiathrough the fourth transmembrane domain were replaced by a PGK-
Homozygous male and female CRFR1 mutant mice were inter-neo cassette (Figure 1). The resulting plasmid DNA was linearized
crossed, and mating was confirmed by the presence of a copulationwith NotI and electroporated into J1 ES cells as described elsewhere
plug (designated embryonic day 0). Beginning on embryonic day(Lee et al., 1992). After selection in 0.2 mg/ml G418 (active form)
12, pregnant females (n 5 3) were treated with 25 mg/ml corticoste-for 7±9 days, neomycin-resistant clones were individually selected.
rone in the drinking water through postnatal day 14, and neonatalApproximately 50% of the cells from each clone were expanded in
survival of offspring was assessed. Lungs from corticosterone-96-well plates for freezing and the remaining 50% in 24-well plates
treated mutantmice, nontreated mutant mice, and untreated controlfor DNA isolation. Colonies were screened for the presence of the
mice were also collectedon postnatal day 1 for histological analysesdisrupted CRFR1 allele by Southern analysis using an external
(n 5 3 each).BamHI-HindIII genomic fragment that hybridized 59 to the targeting
construct (Figure 1A). Cells from two positive ES clones were in-
jected into C57BL/6 blastocysts to generate chimeric mice (Lee et Hormonal Rescue of Adrenal Defect in CRFR1-Deficient Mice
Mutant offspring born using the corticosterone rescue strategy de-al., 1992). Chimeric males were outcrossed to C57BL/6 females
and germ-line transmission of the mutant allele was determined by scribed above were used to determine the effects of ACTH replace-
ment on maturation of the adrenal gland. Briefly, from postnatalSouthern analysis of tail DNA collected from F1 pups displaying
agouti coat color. days 10±21, animals were injected subcutaneously twice daily with
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either 10 ng/g of body weight of rat ACTH in diluent (0.1 M phosphate Statistical Analyses
In the dark±light emergence task, comparisons between the mutantbuffer, 0.1% bovine serum albumin, 0.01% ascorbic acid, pH 7.3)
or with diluent alone. Then, adrenal glands from control mice (n 5 and control mice were performed with the Mann±Whitney U-test.
Student's t-test was used to compare the two groups' locomotor3), ACTH-treated mutant mice (n 5 4), and mutant mice treated with
diluent only (n 5 3) were collected for histological analysis. activity scores. Closed arm entries, percent entries, and percent
time mice spent in the open arms of the elevated plus maze were
analyzed using a two-way ANOVA (strain, drug treatment).Behavioral Analyses
Dark±Light Emergence Task
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